IP Library Granted Patent US 12,613,622
Granted Patent B1
US 12,613,622 · App. 18/925,785 · Granted Apr 28, 2026

Method and system for managing lifestyle and health interventions

Inventors: Kevin Appelbaum (Corte Madera, CA); Mark Berman (San Francisco, CA); Andres Camacho (Lafayette, CA); Sourav Dey (South San Francisco, CA)
Assignee: Click Therapeutics, Inc.
G06F3/0484G16H20/30G16H20/60A61B5/0022G16H50/30
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,613,622
App. No.
18/925,785
Granted
Apr 28, 2026
Kind
B1
Abstract

Provided herein are systems and methods for communicating with user devices over networked environments. A server may provide, to a user device over a communication network, an instruction to present a graphical user interface (GUI) on a user device to prompt a user to input values for event parameters for events on the user device according to a data protocol. The server may receive, from the user device, a plurality of values for a plurality of event parameters The server may determine, based on inputting via the GUI, a metric. The server may apply the plurality of values and the metric into a machine learning model to generate a likelihood to satisfy a target associated with the data protocol. The server may, responsive to the likelihood not satisfying a threshold, transmit a subsequent instruction.

Claims (29)

1 . A system for communicating with user devices over networked environments, comprising:

at least one server having one or more processors coupled with memory, configured to:

provide, to a user device over a communication network, an instruction to present a graphical user interface (GUI) on a user device to prompt a user to input values for a set of compliance parameters for events on the user device according to a data protocol;

receive, from the user device, a plurality of values for the set of compliance parameters inputted via the GUI for the events on the user device;

store, in one or more data structures, the plurality of values for the set of compliance parameters;

track, based on inputting via the GUI, a completion status of at least one of the set of compliance parameters corresponding to at least one event corresponding with achieving a target;

determine, based on tracking, a metric associated with a rate or quality of the plurality of values for the set of compliance parameters;

apply the metric into a machine learning model to generate a likelihood to satisfy a target associated with the data protocol, wherein generating the likelihood comprises comparing the metric to a reference metric of a reference set of users; and

responsive to the likelihood not satisfying a threshold, transmit to the user device over the communication network, a subsequent instruction to prompt the user to input values for the set of compliance parameters for events on the user device according to the data protocol.

2 . The system of claim 1 , wherein the at least one server is further configured to apply the plurality of values and the metric to the machine learning model having one or more weights to (i) identify patterns in user inputs associated with at least one target associated with the data protocol and (ii) generate the likelihood based on the identified patterns.

3 . The system of claim 1 , wherein the at least one server is further configured to determine, based on inputting via the GUI, the metric comprising at least one of a frequency of inputting or a number of inputting by the user.

4 . The system of claim 1 , wherein the at least one server is further configured to generate, in response to the likelihood being below a threshold, the subsequent instruction to prompt the user to input the values for the set of compliance parameters via the GUI according to the data protocol.

5 . The system of claim 1 , wherein the at least one server is further configured to present, in response to the likelihood being below a threshold, the subsequent instruction in a messaging interface with an automated chatbot via the GUI on the user device to prompt the user to enter inputs.

6 . The system of claim 1 , wherein the at least one server is further configured to monitor for inputs via the GUI corresponding to the plurality of values for the set of compliance parameters for events on the user device.

7 . The system of claim 1 , wherein the at least one server is further configured to validate the set of compliance parameters as associated with the target of the data protocol.

8 . A method of communicating with user devices over networked environments, comprising:

providing, by a server to a user device over a communication network, an instruction to present a graphical user interface (GUI) on a user device to prompt a user to input values for a set of compliance parameters for events on the user device according to a data protocol;

receiving, by the server from the user device, a plurality of values for the set of compliance parameters inputted via the GUI for the events on the user device;

storing, by the server, in one or more data structures, the plurality of values for the the set of compliance parameters;

tracking, by the server from the user device, based on inputting via the GUI, a completion status of at least one of the set of compliance parameters corresponding to at least one event corresponding with achieving a target;

determining, by the server, based on tracking, a metric associated a rate or quality of the plurality of values for the set of compliance parameters;

applying, by the server, metric into a machine learning model to generate a likelihood to satisfy a target associated with the data protocol, wherein generating the likelihood comprises comparing the metric to a reference metric of a reference set of users; and

transmitting, by the server to the user device over the communication network responsive to the likelihood not satisfying a threshold, a notification comprising a subsequent instruction to prompt the user to input values for the set of compliance parameters via the GUI according to the data protocol.

9 . The method of claim 8 , wherein applying to the machine learning model further comprises applying the plurality of values and the metric to the machine learning model having one or more weights to (i) identify patterns in inputs associated with at least one target associated with the data protocol and (ii) generate the likelihood based on the identified patterns.

10 . The method of claim 8 , wherein determining the metric further comprises determining, based on inputting via the GUI, the metric comprising at least one of a frequency of inputting or a number of inputting of the plurality of values for the set of compliance parameters by the user.

11 . The method of claim 8 , wherein transmitting the subsequent instruction further comprises generating, in response to the likelihood being below the threshold, the subsequent instruction to prompt the user to input the values for the set of compliance parameters via the GUI according to the data protocol.

12 . The method of claim 8 , wherein transmitting the subsequent instruction further comprises generating, in response to the likelihood being below the threshold, the subsequent instruction to present a messaging interface with an automated chatbot via the GUI on the user device to prompt the user to enter inputs.

13 . The method of claim 8 , further comprising monitoring, by the server, for inputs via the GUI corresponding to the plurality of values for the the set of compliance parameters for events on the user device.

14 . The method of claim 8 , further comprising validating, by the server, the set of compliance parameters as associated with the target of the data protocol.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2025
From: APPELBAUM, KEVIN; BERMAN, MARK; CAMACHO, ANDRES; DEY, SOURAV
To: BETTER THERAPEUTICS, INC.
Reel/Frame 072823/0140 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 7, 2025
From: BETTER THERAPEUTICS, INC.
To: CLICK THERAPEUTICS, INC.
Reel/Frame 072823/0330 →
Continuity (4)
Continuation 15963994 · Apr 26, 2018
Provisional Application 62492065 · Apr 28, 2017
Provisional Application 62628842 · Feb 9, 2018
Provisional Application 62629644 · Feb 12, 2018
References Cited (137)
US 7935307B2 · Angelides · 2011 [cited by applicant]
US 8066640B2 · Angelides · 2011 [cited by applicant]
US 8568309B2 · Angelides · 2013 [cited by applicant]
US 8812244B2 · Angelides · 2014 [cited by applicant]
US 8838513B2 · Sudharsan · 2014 [cited by applicant]
US 9064040B2 · Sudharsan · 2015 [cited by applicant]
US 9516053B1 · Muddu · 2016 [cited by examiner]
US 9536053B2 · Sudharsan · 2017 [cited by applicant]
US 9754077B2 · Sysko et al. · 2017 [cited by applicant]
US 9817559B2 · Simon et al. · 2017 [cited by applicant]
US 9824190B2 · Sudharsan · 2017 [cited by applicant]
US 9858394B2 · Sudharsan · 2018 [cited by applicant]
US 9881136B2 · Sysko et al. · 2018 [cited by applicant]
US 9992292B2 · Gunnarsson et al. · 2018 [cited by applicant]
US 10152675B2 · Sudharsan · 2018 [cited by applicant]
US 10176893B2 · Sysko et al. · 2019 [cited by applicant]
US 10192638B2 · Sysko et al. · 2019 [cited by applicant]
US 10319477B1 · Bill · 2019 [cited by applicant]
US 10672509B2 · Sudharsan · 2020 [cited by applicant]
US 10748658B2 · McRaith et al. · 2020 [cited by applicant]
US 10818389B2 · Sysko et al. · 2020 [cited by applicant]
US 10839951B2 · Sysko et al. · 2020 [cited by applicant]
US 10846607B2 · Sysko et al. · 2020 [cited by applicant]
US 10854337B2 · McRaith et al. · 2020 [cited by applicant]
US 10860943B2 · Sysko et al. · 2020 [cited by applicant]
US 10872686B2 · Sysko et al. · 2020 [cited by applicant]
US 10978207B2 · McRaith et al. · 2021 [cited by applicant]
US 11355228B2 · Appelbaum et al. · 2022 [cited by applicant]
US 20070072156A1 · Kaufman et al. · 2007 [cited by applicant]
US 20070288266A1 · Sysko et al. · 2007 [cited by applicant]
US 20080299009A1 · Angelides · 2008 [cited by applicant]
US 20090264337A1 · Angelides · 2009 [cited by applicant]
US 20100191075A1 · Angelides · 2010 [cited by applicant]
US 20110046519A1 · Raheman · 2011 [cited by applicant]
US 20110119075A1 · Dhoble · 2011 [cited by applicant]
US 20110125519A1 · Dhoble · 2011 [cited by applicant]
US 20110125520A1 · Dhoble · 2011 [cited by applicant]
US 20120029327A1 · Angelides · 2012 [cited by applicant]
US 20120231431A1 · Angelides · 2012 [cited by applicant]
US 20130035563A1 · Angelides · 2013 [cited by applicant]
US 20130078601A1 · Angelides · 2013 [cited by applicant]
US 20130110551A1 · Bingol · 2013 [cited by applicant]
US 20130117040A1 · James et al. · 2013 [cited by applicant]
US 20130187780A1 · Angelides · 2013 [cited by applicant]
US 20130216989A1 · Cuthbert · 2013 [cited by applicant]
US 20140052475A1 · Madan et al. · 2014 [cited by applicant]
US 20140074454A1 · Brown · 2014 [cited by examiner]
US 20140089836A1 · Damani et al. · 2014 [cited by applicant]
US 20140154653A1 · Angelides · 2014 [cited by applicant]
US 20140214442A1 · Duffy et al. · 2014 [cited by applicant]
US 20140214443A1 · Duffy et al. · 2014 [cited by applicant]
US 20140222454A1 · Duffy et al. · 2014 [cited by applicant]
US 20140278474A1 · McClure · 2014 [cited by examiner]
US 20140363794A1 · Angelides · 2014 [cited by applicant]
US 20150079561A1 · Petakov et al. · 2015 [cited by applicant]
US 20150281384A1 · Gunnarsson et al. · 2015 [cited by applicant]
US 20150288797A1 · Vincent · 2015 [cited by applicant]
US 20150313529A1 · Nevo et al. · 2015 [cited by applicant]
US 20150371007A1 · Cederlund et al. · 2015 [cited by applicant]
US 20160012342A1 · Simon et al. · 2016 [cited by applicant]
US 20160321935A1 · Mohler · 2016 [cited by examiner]
US 20160324463A1 · Simpson et al. · 2016 [cited by applicant]
US 20170076630A1 · Angelides et al. · 2017 [cited by applicant]
US 20170080288A1 · Roh · 2017 [cited by examiner]
US 20170109479A1 · Vemireddy et al. · 2017 [cited by applicant]
US 20170162069A1 · Petakov et al. · 2017 [cited by applicant]
US 20170228520A1 · Kidd et al. · 2017 [cited by applicant]
US 20170329917A1 · McRaith et al. · 2017 [cited by applicant]
US 20170329933A1 · Brust et al. · 2017 [cited by applicant]
US 20170344726A1 · Duffy et al. · 2017 [cited by applicant]
US 20180180633A1 · Volek et al. · 2018 [cited by applicant]
US 20180247713A1 · Rothman · 2018 [cited by applicant]
US 20180277246A1 · Zhong et al. · 2018 [cited by applicant]
US 20180315499A1 · Appelbaum et al. · 2018 [cited by applicant]
US 20190074080A1 · Appelbaum et al. · 2019 [cited by applicant]
US 20200335218A1 · McRaith et al. · 2020 [cited by applicant]
US 20200383571A1 · Fakhouri et al. · 2020 [cited by applicant]
US 20200383648A1 · Bridgewater et al. · 2020 [cited by applicant]
US 20200388376A1 · Kendale · 2020 [cited by applicant]
US 20200388381A1 · Kozin et al. · 2020 [cited by applicant]
US 20200388392A1 · Chen et al. · 2020 [cited by applicant]
US 20200388393A1 · Boulos et al. · 2020 [cited by applicant]
US 20200388399A1 · Kozin et al. · 2020 [cited by applicant]
US 20200388403A1 · Boulos et al. · 2020 [cited by applicant]
US 20210035690A1 · McRaith et al. · 2021 [cited by applicant]
US 20210104173A1 · Pauley · 2021 [cited by examiner]
US 20210272474A1 · Geronimo-Button · 2021 [cited by examiner]
US 20220061775A1 · Jepson · 2022 [cited by examiner]
US 20220062621A1 · Hogg · 2022 [cited by examiner]
US 20220375619A1 · Appelbaum et al. · 2022 [cited by applicant]
US 20220392611A1 · Appelbaum et al. · 2022 [cited by applicant]
US 20230017196A1 · Jain · 2023 [cited by examiner]
WO WO2017106770A1 · 2017 [cited by applicant]
WO 2020061562A1 · 2020 [cited by applicant]
WO 2020247032A1 · 2020 [cited by applicant]
Berman et al.: “FareWell and the How of Lifestyle Medicine”, American Journal of Lifestyle Medicine, vol. 11, No. 4, Apr. 6, 2017 (Apr. 6, 2017), pp. 314-317, XP009506081, DOI: 10.1177/1559827617701411. [cited by applicant]
Berman: “Learning & Outcomes from our First Digital Therapeutic Pilot”, Feb. 16, 2017 (Feb. 16, 2017), XP55484428; Retrieved from the internet: https://farewell-assets.s3.amazonaws.com/Pilot_Results_Extended_Referenced_… [cited by applicant]
Berman: “Learning & Outcomes From Our First Digital Therapeutic Pilot” Feb. 10, 2017, Retrieved from: https://farewell-assets.s3.amazonaws.com/Pilot_Results_Extended_Referenced_Version.pdf. [cited by applicant]
Comstock: “FareWell raises $8.5M for digital coaching weight loss service”, Jun. 23, 2016; Retrieved from: https://www.mobihealthnews.com/content/farewell-raises-85m-digital-coaching-weight-lossservice. [cited by applicant]
Comstock: “Farewell raises $8.5m for Digital Coaching Weight Loss Service”, MobiHealthNews, Jun. 23, 2016 (Jun. 23, 2016), XP002782054, Retrieved from the internet: https://www.mobihealthnews.com/content/farewell-raises… [cited by applicant]
Coughlin, et al., “Smartphone Applications for Promoting Healthy Diet and Nutrition: A Literature Review” Jacobs J Food Nutr. 2015;2(3):021. Retrieved from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4725321/pdf/nihms… [cited by applicant]
Coughlin: “Smartphone Applications for Promoting Healthy Diet and Nutrition: A Literature Review”, Jacobs J Food Nutr., Jan. 25, 2016 (Jan. 25, 2016), XP55484530, Retrieved from the internet: https://www.ncbi.nlm.nih.go… [cited by applicant]
Examination Report on EP Appl. No. 18724093.2 dated Nov. 15, 2024. [cited by applicant]
Examiner's Report for CA Appl. No. 3,061,729 dated Feb. 29, 2024. [cited by applicant]
Examiner's Report for CA Appl. No. 3,061,729 dated Mar. 19, 2024. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/963,994 dated Mar. 30, 2023. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/963,994 dated May 24, 2024. [cited by applicant]
Final Office Action for U.S. Appl. No. 15/963,994 dated Nov. 17, 2021. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/963,994 dated Apr. 28, 2022. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/963,994 dated Feb. 19, 2021. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 15/963,994 dated Oct. 23, 2023. [cited by applicant]
Non-Final Office Action for U.S. Appl. No. 17/833,623 dated Jul. 31, 2024. [cited by applicant]
Non-Final Office Action on US No. U.S. Appl. No. 17/833,625 dated Sep. 12, 2024. [cited by applicant]
Sforzo: “A Digital Therapy using Wellcoaches Model”, Blog entry; Wellcoaches, School of coaching; Mar. 13, 2017 (Mar. 13, 2017); Retrieved from the internet: https://www.wellcoachesschool.com/post/a-digital-therapy-usin… [cited by applicant]
Final Office Action on U.S. Appl. No. 17/833,623 dated May 7, 2025. [cited by applicant]
Final Office Action on U.S. Appl. No. 17/833,625 dated May 30, 2025. [cited by applicant]
Anonymous (Apr. 9, 2016. e-pub. Apr. 6, 2016). “Worldwide Trends in Diabetes Since 1980: A Pooled Analysis of 751 Population-Based Studies with 4.4 Million Participants,” NCO Risk Factor Collaboration (NCO-Rise): The La… [cited by applicant]
Anonymous (Apr. 2013). “Economic Costs of Diabetes in the U.S. in 2012,” Diabetes Care 36(4):1033-1046. [cited by applicant]
Barnard, N.D et al. (2009). “A Low-Fat Vegan Diet and a Conventional Diabetes Diet in the Treatment of Type 2 Diabetes: A Randomized, Controlled, 74-Wk Clinical Trial,” Am. J. Clin. Nutr. 89:15885-15968. [cited by applicant]
Decision to grant received for European Application No. 18724423.1, mailed on May 11, 2023, 3 pages. [cited by applicant]
European Search Report received for European Application No. 25172392.0, mailed on Aug. 8, 2025, 14 pages. [cited by applicant]
Intention to grant received for European Application No. 18724423.1, mailed on Jan. 2, 2023, 6 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT application No. PCT/US2018/029653, mailed on Nov. 7, 2019, 13 pages. [cited by applicant]
International Preliminary Report on Patentability received for PCT application No. PCT/US2018/029654, mailed on Nov. 7, 2019, 17 pages. [cited by applicant]
International search Report and written opinion received for PCT application No. PCT/US2018/029653, mailed on Jul. 18, 2018, 15 pages. [cited by applicant]
International search Report and written opinion received for PCT application No. PCT/US2018/029654, mailed on Sep. 11, 2018, 22 pages. [cited by applicant]
Invitation to Pay Additional Fees received for PCT application No. PCT/US2018/029654, mailed on Jul. 18, 2018, 16 pages. [cited by applicant]
Jenkins, D.J.A et al. (2002). “A Dietary Portfolio Approach to Cholesterol Reduction: Combined Effects of Plant Sterols, Vegetable Proteins, and Viscous Fibers in Hypercholesterolemia Metabolism,” 51:1596-1604. [cited by applicant]
Krittanawong, C et al. (May 30, 2017). “Artificial Intelligence in Precision Cardiovascular Medicine,” JACC Journals Archives 69(21):2657-2664. [cited by applicant]
National Diabetes Statistics Report 2017: Centers for Disease Control and Prevention, U.S. Department of Health and Human Services, URL: www.cdc.gov/diabetes/library/reports/congress/html, 16 pages. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 18/925,785 dated Apr. 10, 2025. [cited by applicant]
Non-Final Office Action on U.S. Appl. No. 18/925,785 dated Jan. 13, 2025. [cited by applicant]
Notification of Oral Proceeding received for European Application No. 18724423.1, mailed on May 23, 2022, 12 pages. [cited by applicant]
Office Action received for European Application No. 18724093.2, mailed on Jun. 14, 2022, 4 pages. [cited by applicant]
Partial OA Response dated Apr. 23, 2024, Squire Patton Boggs LLP, 6 pages. [cited by applicant]
Shahraz, S. et al. (2017, e-pub. Nov. 14, 2017). “Change in Testing, Awareness of Hemoglobin A1c Result, and Glycemic Control in US Adults, 2007-2014,” JAMA 318(18):1825-1827. [cited by applicant]
Shi, Y et al. (Jun. 7, 2014, e-pub. Mar. 7, 2014). “The Global Implications of Diabetes and Cancer,” Lancet 383 (9933):1947-1948. [cited by applicant]